• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Rani Therapeutics could go the IPO route

January 30, 2020 By Sean Whooley

Rani TherapeuticsRani Therapeutics is reportedly moving forward with an early-stage efficacy and safety study for its robotic pills and may be on its way toward the possibility of an IPO.

According to a report in Endpoints News, Rani, led by CEO Mir Imran who shared the story on LinkedIn, revealed that its RaniPill performed as expected with 58 healthy adult volunteers in distributing octreotide to treat hormonal disorder acromegaly.

The RaniPill is designed with an enteric coating to protect it from the acid of the stomach. Once in the intestine, a chemical reaction takes place to inflate a balloon and push a dissolvable microneedle filled with a drug into the intestinal wall. The pill is supposed to be an alternative to traditional injections.

Imran told Endpoints News that the company has raised $142 million in funding and is expecting more, with an IPO becoming a “distinct possibility” about a year from now.

The report shared that among the investors in the company so far are Alphabet’s (NSDQ:GOOG) Google Ventures, Novartis (NYSE:NVS) and Takeda-owned (TYO:4502) Shire (NSDQ:SHPG).

Imran, who is known for his work on the first FDA-approved implantable cardioverter defibrillator, told Drug Delivery News in a June 2018 interview that he is seeking to make a big difference in the drug delivery space.

“Very few drug-delivery platforms will have such a profound impact on so many chronic diseases,” Imran said in 2018. “I’m trying to get that message across because this could be a huge benefit to the patients, to the payers and for the doctors who are treating these patients.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Initial Public Offering (IPO) Tagged With: ranitherapeutics

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS